Partner, Atlas Venture
Jason Rhodes is a partner at Atlas Venture and focuses on creating and building novel therapeutics companies.
Jason is the chairman and was the founding CEO of Dyne Therapeutics (NASDAQ: DYN), Rectify Pharmaceuticals, and of Generation Bio (NASDAQ: GBIO). He was the chairman and founding CEO of Disarm Therapeutics prior to its acquisition by Eli Lilly in 2020. Prior to Atlas Venture, Jason was President and CFO at Epizyme Therapeutics, led business development at Alnyalm (NASDAQ: ALNY), and was a partner with Fidelity Biosciences (now F-Prime), the biotech venture arm of Fidelity Investments.
Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.